Respiri Limited
Marjan Mikel is the CEO/Managing Director of Respiri Limited, where Marjan leads a Remote Patient Monitoring (RPM) Business augmented by R&D. Marjan also serves as an Industry Research Fellow at UNSW and has held various leadership roles in companies such as Memphasys Ltd, Portt, Cyclonas, and Healthmatics Pty Ltd. Marjan Mikel's educational background includes a MAICD in Business Administration, Management and Operations from AGSM @ UNSW Business School, a MCom in Masters of Commerce from UNSW, and other degrees in geology, geography, chemistry, and education.
This person is not in any teams
Respiri Limited
An RPM Business Augmented by R&D Respiri Limited (ASX:RSH, OTCQB:RSHUF) is a pioneering presence in the Remote Patient Monitoring (RPM) and MedTech sectors. The company uses its innovative respiratory technology with a disruptive business model as an RPM provider to offer the only RPM program for respiratory disorders. As a differentiated RPM provider, Respiri’s mission is to improve health outcomes for patients with chronic diseases from cardiovascular, diabetes, obesity and, exclusively, respiratory disease. Respiri’s globally unique medical device and its Remote Patient Monitoring services empower healthcare organisations to take action from patient data when needed, not only when scheduled. Respiri is strategically positioned to revolutionise chronic disease management globally and is focused on the US market, where RPM services are reimbursed by Current Procedural Terminology (CPT) Code reimbursement.